MCID: OLF005
MIFTS: 46

Olfactory Neuroblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Olfactory Neuroblastoma

MalaCards integrated aliases for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma 12 20 58 15 17 70
Esthesioneuroblastoma 12 73 20 58 54
Paranasal Sinus Olfactory Neuroblastoma 12
Esthesioneuroblastoma, Olfactory 44
Olfactory Esthesioneuroblastoma 12
Esthesioneuroepithelioma 12
Asthesioneuroblastoma 12

Characteristics:

Orphanet epidemiological data:

58
esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:369
MeSH 44 D018304
NCIt 50 C3789
SNOMED-CT 67 76060004
ICD10 via Orphanet 33 C30.0
UMLS via Orphanet 71 C0206717
Orphanet 58 ORPHA1957
UMLS 70 C0206717

Summaries for Olfactory Neuroblastoma

GARD : 20 Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood. Symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor, facial pain, runny nose, and nosebleeds. Treatment usually includes surgery to remove the tumor, radiation therapy, and sometimes chemotherapy.

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to nasal cavity olfactory neuroblastoma and sinonasal undifferentiated carcinoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Bevacizumab and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include endothelial, pituitary and lymph node, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 73 Esthesioneuroblastoma, is a rare cancer of the nasal cavity. Arising from the upper nasal tract,... more...

Related Diseases for Olfactory Neuroblastoma

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 476)
# Related Disease Score Top Affiliating Genes
1 nasal cavity olfactory neuroblastoma 32.6 SYP NKX2-1 ENO2
2 sinonasal undifferentiated carcinoma 31.1 SYP ENO2
3 neuroblastoma 30.9 SYP SHH NTRK2 NTRK1 EWSR1 ENO2
4 paraganglioma 30.5 SYP S100B ENO2 CHGA
5 intracranial cysts 30.4 S100B ENO2
6 spindle cell sarcoma 30.3 VIM S100B EWSR1
7 adrenal neuroblastoma 30.3 SYP NTRK1 ENO2 CHGA
8 central neurocytoma 30.2 SYP ENO2 CHGA
9 neuroendocrine carcinoma 30.2 SYP S100B PTPRC NKX2-1 ENO2 CHGA
10 gangliocytoma 30.2 SYP ENO2
11 malignant teratoma 30.0 SYP ENO2 CD99
12 meningioma, familial 29.9 VIM SYP SSTR2 S100B CALB2
13 askin's tumor 29.9 SYP EWSR1 ENO2 CD99
14 ganglioneuroblastoma 29.8 SYP S100B NTRK2 NTRK1 ENO2
15 leiomyosarcoma 29.7 VIM S100B MB ENO2
16 carcinosarcoma 29.7 VIM MB CALB2
17 small cell carcinoma 29.7 SYP PTPRC NKX2-1 ENO2 CHGA
18 small cell cancer of the lung 29.7 SYP PTPRC NKX2-1 ENO2 CHGA
19 hemangioma 29.6 VIM SYP NKX2-1 ENO2 CHGA
20 neuroendocrine tumor 29.6 SYP SSTR2 NKX2-1 ENO2 CHGA
21 pheochromocytoma 29.5 VIM SYP NTRK1 ENO2 CHGA CALB2
22 ewing sarcoma 29.4 VIM SYP S100B PTPRC EWSR1 ENO2
23 merkel cell carcinoma 29.3 SYP PTPRC NKX2-1 ENO2 CHGA CD99
24 ganglioneuroma 29.2 SYP S100B NTRK2 NTRK1 ENO2 CHGA
25 teratoma 28.8 SYP SHH NKX2-1 ENO2 CHGA CD99
26 rhabdomyosarcoma 28.0 VIM SYP SHH S100B PTPRC MB
27 rare tumor 10.5
28 malignant melanocytic neoplasm of the peripheral nerve sheath 10.4 SYP ENO2
29 vaginal glandular tumor 10.4 ENO2 CHGA
30 ureter transitional cell carcinoma 10.4 ENO2 CHGA
31 glomangioma 10.4 VIM SYP
32 anal neuroendocrine tumor 10.4 SYP ENO2
33 optic nerve astrocytoma 10.4 SYP ENO2
34 cerebral neuroblastoma 10.4 SYP ENO2
35 neuronal intestinal dysplasia, type b 10.4 SYP ENO2
36 gastric gastrinoma 10.4 ENO2 CHGA
37 multiple mucosal neuroma 10.4 NTRK1 ENO2
38 cloacogenic carcinoma 10.4 SYP ENO2
39 pineal region teratoma 10.4 SYP ENO2
40 bile duct mucinous adenocarcinoma 10.4 SYP ENO2
41 papillary ependymoma 10.4 SYP S100B
42 nodular prostate 10.4 SYP ENO2
43 esophageal neuroendocrine tumor 10.4 SYP CHGA
44 goblet cell carcinoid 10.4 ENO2 CHGA
45 meningeal melanocytoma 10.4 S100B ENO2
46 cerebellar liponeurocytoma 10.4 SYP ENO2
47 acinar cell cystadenocarcinoma 10.4 SYP CHGA
48 vulvar eccrine porocarcinoma 10.4 SYP CHGA
49 pancreatic serous cystadenocarcinoma 10.4 SYP CHGA
50 gastrointestinal neuroendocrine benign tumor 10.4 SYP CHGA

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:



Diseases related to Olfactory Neuroblastoma

Symptoms & Phenotypes for Olfactory Neuroblastoma

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.7 SSTR2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 9.7 CHGA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 9.7 EWSR1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.7 EWSR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 9.7 EWSR1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 9.7 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.7 SSTR2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 9.7 CHGA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 9.7 CHGA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.7 SSTR2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-215 9.7 CHGA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.7 EWSR1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-52 9.7 EWSR1 NTRK1 SSTR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.7 EWSR1 SSTR2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 9.7 SSTR2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.7 CHGA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 9.7 CHGA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.7 EWSR1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 9.7 EWSR1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.7 EWSR1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.7 SSTR2

MGI Mouse Phenotypes related to Olfactory Neuroblastoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 CALB2 ENO2 ISL1 NKX2-1 NTRK1 NTRK2
2 nervous system MP:0003631 9.93 CALB2 CHGA ENO2 ISL1 NKX2-1 NTRK1
3 normal MP:0002873 9.65 CALB2 ISL1 NKX2-1 NTRK1 NTRK2 PTPRC
4 respiratory system MP:0005388 9.17 ENO2 MB NKX2-1 NTRK2 PTPRC SHH

Drugs & Therapeutics for Olfactory Neuroblastoma

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
2
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
3
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
4
Etoposide Approved Phase 2 33419-42-0 36462
5
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
6
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
7 Protein Kinase Inhibitors Phase 1, Phase 2
8 Angiogenesis Inhibitors Phase 1, Phase 2
9 Immunoglobulins Phase 1, Phase 2
10 Antibodies Phase 1, Phase 2
11 Antineoplastic Agents, Immunological Phase 1, Phase 2
12 Immunoglobulins, Intravenous Phase 1, Phase 2
13 Antibodies, Monoclonal Phase 1, Phase 2
14 Immunologic Factors Phase 1, Phase 2
15
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
16 Neurotransmitter Agents Phase 1, Phase 2
17 Fluorides Phase 1, Phase 2
18 Fluorodeoxyglucose F18 Phase 1, Phase 2
19 Radiopharmaceuticals Phase 1, Phase 2
20 Arginyl-glycyl-aspartic acid Phase 1, Phase 2
21 N-Methylaspartate Phase 1, Phase 2
22 Etoposide phosphate Phase 2
23
Arginine Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
24
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
25
Hydroxyurea Approved Phase 1 127-07-1 3657
26
Fluorouracil Approved Phase 1 51-21-8 3385
27
Lenograstim Approved, Investigational Phase 1 135968-09-1
28
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
29
Sirolimus Approved, Investigational Phase 1 53123-88-9 6436030 5284616
30
7-hydroxystaurosporine Experimental, Investigational Phase 1 112953-11-4 72271
31 topoisomerase I inhibitors Phase 1
32 Mitogens Phase 1
33 Immunosuppressive Agents Phase 1
34 Antimetabolites Phase 1
35 Endothelial Growth Factors Phase 1
36 Liver Extracts Phase 1
37 Cola Phase 1
38
Gefitinib Approved, Investigational 184475-35-2 123631
39
Somatostatin Approved, Investigational 38916-34-6, 51110-01-1 53481605

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
2 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
3 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
4 A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors Active, not recruiting NCT03274414 Phase 2 Cisplatin;cisplatin and etoposide
5 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
6 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
7 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
8 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
9 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
10 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
11 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
12 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
13 68Ga(Gallium)-DOTATATE Positron Emission Tomography (PET)/MRI in the Diagnosis and Management of Somatostatin Receptor Positive Central Nervous System CNS Tumors. Recruiting NCT04081701
14 A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery Recruiting NCT04087902
15 A Phase II Study of Intensity-Modulated or Proton Radiation Therapy for Locally Advanced Sinonasal Malignancy Recruiting NCT01586767
16 A Natural History Study of Children and Adults With Olfactory Neuroblastoma Not yet recruiting NCT04755205
17 Esthesioneuroblastoma: Outcomes After Treatment Withdrawn NCT02580136

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Genetic Tests for Olfactory Neuroblastoma

Anatomical Context for Olfactory Neuroblastoma

MalaCards organs/tissues related to Olfactory Neuroblastoma:

40
Endothelial, Pituitary, Lymph Node, Eye, Liver, Bone Marrow, Spinal Cord

Publications for Olfactory Neuroblastoma

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 1286)
# Title Authors PMID Year
1
Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma. 54 61
19386345 2009
2
[Advances in the diagnosis of ENT tumors in childhood]. 61 54
12724079 2003
3
[Co-expression of TrkA and p75 neurotrophin receptor in extracranial olfactory neuroblastoma cells]. 61 54
12934398 2003
4
Co-expression of trkA and p75 neurotrophin receptor in extracranial olfactory neuroblastoma cells. 54 61
12175342 2002
5
Primary mucosal melanomas of the nasal cavity and paranasal sinuses. A clinicopathological analysis of 14 cases. 61 54
9548430 1998
6
Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. 61 54
8630875 1995
7
Olfactory neuroblastoma. Additional immunohistochemical characterization. 61 54
1700595 1990
8
C19MC amplification and expression of Lin28A and Olig2 in the classification of embryonal tumors of the central nervous system: A 14-year retrospective study from a tertiary care center. 61
33236184 2021
9
[Clinical analysis of 31 cases of esthesioneuroblastoma]. 61
33794633 2021
10
Proposal of a TNM classification-based staging system for esthesioneuroblastoma: More precise prediction of prognosis. 61
33301222 2021
11
Consolidating the Hyams grading system in esthesioneuroblastoma - an individual participant data meta-analysis. 61
33770323 2021
12
68Ga-DOTATOC PET/CT and MR in the Evaluation of Meningeal Metastasis From Esthesioneuroblastoma: A Case Report. 61
33782294 2021
13
Characteristics and overall survival in pediatric versus adult esthesioneuroblastoma: A population-based study. 61
33812144 2021
14
Outcomes and Quality of Life Measures after Endoscopic Endonasal Resection of Kadish Stage C Olfactory Neuroblastomas. 61
33798777 2021
15
[Diagonistic and prognostic analysis of olfactory neuroblastoma]. 61
33794606 2021
16
The value of 68 Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series. 61
33786927 2021
17
Utility of CT texture analysis to differentiate olfactory neuroblastoma from sinonasal squamous cell carcinoma. 61
33633160 2021
18
Review of the cytological features of olfactory neuroblastoma: A retrospective single-center study. 61
33629822 2021
19
Facial disfigurement due to olfactory neuroblastoma: beauty regained with chemotherapy. 61
33029949 2021
20
Clinico-pathological Profile of Head and Neck Tumours with Intracranial Extension. 61
33641147 2021
21
Comparison of Open and Endoscopic Approaches in the Resection of Esthesioneuroblastoma. 61
32627574 2021
22
Late Intramedullary Spinal Metastases from Esthesioneuroblastoma: Case Report and Prognostic Implications. 61
32818694 2021
23
Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma. 61
33747939 2021
24
Primary Olfactory Neuroblastoma of the Nasopharynx: A Case Report. 61
33474978 2021
25
Radiation-induced intracranial osteosarcoma of the anterior skull base after treatment of esthesioneuroblastoma. 61
33462035 2021
26
Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma. 61
32558242 2021
27
A Rare Case of Ectopic Adrenocorticotropic Hormone Syndrome with Recurrent Olfactory Neuroblastoma. 61
32921682 2021
28
Development and validation of a postoperative nomogram for predicting overall survival after endoscopic surgical management of olfactory neuroblastoma. 61
33305194 2020
29
Primary Olfactory Neuroblastoma Masquerading as a Pituitary Adenoma : Case Report and Review of the Literature. 61
32385516 2020
30
Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase. 61
32424573 2020
31
A rare case of ovarian metastasis of esthesioneuroblastoma: A case report. 61
32687603 2020
32
Extraprimary Local Recurrence of Esthesioneuroblastoma: Case Series and Literature Review. 61
32916346 2020
33
Geographic and Socioeconomic Factors on Survival in Esthesioneuroblastoma. 61
33347619 2020
34
Orbital invasion by Esthesioneuroblastoma: a comparative case series and review of literature. 61
33317383 2020
35
Occult olfactory neuroblastoma presenting with multiple bone metastases: a case report. 61
33235061 2020
36
Surgery as Single-Modality Treatment for Early-Stage Olfactory Neuroblastoma: An Institutional Experience, Systematic Review and Meta-analysis. 61
33174762 2020
37
A novel nomogram to predict the overall survival in esthesinoeroblastoma. 61
33054751 2020
38
Limited utility of 5-ALA optical fluorescence in endoscopic endonasal skull base surgery: a multicenter retrospective study. 61
33126212 2020
39
Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. 61
32573984 2020
40
Computed Tomography Image Analysis and Clinical Diagnosis Value of Nasal Olfactory Neuroblastoma. 61
33039569 2020
41
Short-Term Morbidity and Predictors of Adverse Events Following Esthesioneuroblastoma Surgery. 61
33121257 2020
42
Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas: a single center results of 138 patients. 61
32948223 2020
43
Extensive tumor calcification in response to pre-operative reductive chemotherapy in pediatric esthesioneuroblastoma: a case report. 61
32100079 2020
44
Esthesioneuroblastoma in children, adolescents and young adults. 61
32896369 2020
45
Comparing Kadish and Modified Dulguerov Staging Systems for Olfactory Neuroblastoma: An Individual Participant Data Meta-analysis. 61
32286935 2020
46
Mixed Olfactory Neuroblastoma and Adenocarcinoma with In Situ Neuroendocrine Hyperplasia. 61
31388897 2020
47
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. 61
32005769 2020
48
Incisionless facial resection for Kadish stage C olfactory neuroblastoma: Transcaruncular approach with combined endonasal and skull base surgery. 61
32884782 2020
49
Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma. 61
32953726 2020
50
Case report expanding the germline AXIN2- related phenotype to include olfactory neuroblastoma and gastric adenoma. 61
32807118 2020

Variations for Olfactory Neuroblastoma

Copy number variations for Olfactory Neuroblastoma from CNVD:

7 (show all 31)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 31526 1 28000000 30200000 Gain Olfactory neuroblastoma
2 34250 1 5400000 7200000 Gain Olfactory neuroblastoma
3 41470 10 18700000 22600000 Gain Olfactory neuroblastoma
4 63735 12 120700000 125900000 Gain Olfactory neuroblastoma
5 74688 13 110300000 115169878 Gain CUL4A Olfactory neuroblastoma
6 74689 13 110300000 115169878 Gain TFDP1 Olfactory neuroblastoma
7 75167 13 17900000 115169878 Gain Olfactory neuroblastoma
8 77744 13 47300000 55300000 Gain Olfactory neuroblastoma
9 79881 13 79000000 87700000 Gain Olfactory neuroblastoma
10 91527 15 31200000 33600000 Gain Olfactory neuroblastoma
11 101890 16 47000000 52600000 Gain Olfactory neuroblastoma
12 150427 20 1 27500000 Gain Olfactory neuroblastoma
13 151980 20 27500000 63025520 Gain Olfactory neuroblastoma
14 152120 20 29400000 37600000 Gain Olfactory neuroblastoma
15 154980 20 5100000 12100000 Gain Olfactory neuroblastoma
16 155529 20 56500000 63025520 Gain PTK6 Olfactory neuroblastoma
17 159453 21 42600000 48129895 Gain Olfactory neuroblastoma
18 163221 22 25900000 29600000 Gain Olfactory neuroblastoma
19 179990 4 1 6000000 Gain Olfactory neuroblastoma
20 181394 4 120800000 191154276 Gain Olfactory neuroblastoma
21 184608 4 17800000 48200000 Gain Olfactory neuroblastoma
22 187607 4 52700000 59500000 Gain Olfactory neuroblastoma
23 190046 4 82400000 93700000 Gain Olfactory neuroblastoma
24 196156 5 159900000 168500000 Gain Olfactory neuroblastoma
25 196538 5 168500000 180915260 Gain Olfactory neuroblastoma
26 213457 6 46200000 51800000 Gain Olfactory neuroblastoma
27 227898 7 72200000 77500000 Gain FZD9 Olfactory neuroblastoma
28 227899 7 72200000 77500000 Gain LIMK1 Olfactory neuroblastoma
29 228591 7 77500000 86400000 Gain Olfactory neuroblastoma
30 251884 9 33200000 36300000 Gain Olfactory neuroblastoma
31 257109 X 1 155270560 Gain Olfactory neuroblastoma

Expression for Olfactory Neuroblastoma

Search GEO for disease gene expression data for Olfactory Neuroblastoma.

Pathways for Olfactory Neuroblastoma

Pathways related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 SYP S100B NTRK2 NTRK1 NKX2-1 ENO2
2 10.92 VIM SYP SHH S100B ISL1
3
Show member pathways
10.3 NTRK2 NTRK1
4 10.11 SHH NKX2-1

GO Terms for Olfactory Neuroblastoma

Cellular components related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 8.8 SYP NTRK2 CALB2

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 9.67 PTPRC NTRK2 NTRK1
2 innervation GO:0060384 9.56 NTRK1 ISL1
3 intermediate filament organization GO:0045109 9.55 VIM SHH
4 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 SHH NKX2-1
5 forebrain development GO:0030900 9.54 SSTR2 SHH NKX2-1
6 regulation of protein kinase B signaling GO:0051896 9.52 NTRK2 NTRK1
7 anatomical structure formation involved in morphogenesis GO:0048646 9.51 SHH NKX2-1
8 peripheral nervous system neuron development GO:0048935 9.48 NTRK2 ISL1
9 negative thymic T cell selection GO:0045060 9.46 SHH PTPRC
10 positive thymic T cell selection GO:0045059 9.43 SHH PTPRC
11 Bergmann glial cell differentiation GO:0060020 9.4 VIM SHH
12 stem cell development GO:0048864 9.32 SHH PTPRC
13 mechanoreceptor differentiation GO:0042490 9.26 NTRK2 NTRK1
14 neurotrophin signaling pathway GO:0038179 9.16 NTRK2 NTRK1
15 oligodendrocyte differentiation GO:0048709 9.13 SHH NTRK2 NKX2-1
16 neuron fate commitment GO:0048663 8.8 SHH NKX2-1 ISL1

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotrophin binding GO:0043121 8.96 NTRK2 NTRK1
2 neurotrophin receptor activity GO:0005030 8.62 NTRK2 NTRK1

Sources for Olfactory Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....